|
1. BIOLOGIE
| |
|
|
HeLa Cells from Different Labs Vary in Genetics, Phenotype [The Scientist]
| |
|
| |
|
This latest investigation is the first comprehensive analysis of genetic variation across a wide range of HeLa variants—different batches of HeLa cells that live in various labs around the world—and the first to demonstrate that the genetic heterogeneity results in changes in protein expression and phenotype.
| |
| | |
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
| |
|
Yes we can, EUCANCan! [VHIO]
| |
| | |
|
A total of 18 partners with aligned strategies have joined forces as a carefully pieced model to provide a functional platform for federated genome analysis systems towards efficiently analyzing, managing, sharing and reusing mass genomic data at a global level.
| |
| | |
|
|
5. TRAITEMENTS
| |
|
Proteasome Inhibitors, Refined [In The Pipeline]
| |
| | |
|
Now, this list might be seen as an egregious example of “me-too” drugs gone crazy. How, you wonder, did the world end up with so many proteasome inhibitors, especially since several of them look so similar to others in the same class? Because they’re still different.
| |
| | |
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
| |
|
|
5.10 TRAITEMENTS - ESSAIS
| |
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
| |
|
Immatics, Roche ally to trial Tecentriq with cell therapy [Fierce Biotech]
| |
| | |
|
IMA101 consists of cytotoxic T lymphocytes selected to recognize up to four targets expressed by the patient’s tumor. By expanding the cells and readministering them back into the patient, Immatics thinks it can create treatments that overcome the relapse and target specificity problems that have stopped adoptive cellular therapies from gaining traction in solid tumors to date.
| |
| | |
|
|
|
|
5.2 PHARMA
| |
|
|
|
5.2.1 PHARMA - PARTENARIATS
| |
|
|
5.2.2 PHARMA - FUSIONS & ACQUISITIONS
| |
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
| |
|
|
5.9 AACR
| |
|
|
5.9.10 AACR - COLORECTAL
| |
|
|
5.9.12 AACR - BIOPSIES LIQUIDES
| |
|
|
|
5.9.9 AACR - IMMUNOTHÉRAPIES
| |
|
|
6. LUTTE CONTRE LES CANCERS
| |
|
|
6.1 OBSERVATION
| |
|
|
|
6.10.1 POLITIQUES (USA)
| |
|
|
|
|
|
6.4 MÉDICO-ÉCO
| |
|
|
6.6 PUBLICATIONS
| |
|
|
6.8 COMMUNICATION
| |
|
|
6.9 CONTROVERSES
| |
|
Simon Rule and Steven LeGouill: Bureaucracy is strangling clinical research [BMJ]
| |
|
| |
|
This opinion piece has been signed by almost 1000 senior researchers in haematology from across Europe. Most have been involved with clinical research for years and are fortunate in having research teams around them that help with this ever-increasing workload, but for new investigators without any infrastructure to support them clinical research has become too time consuming and challenging to engage with.
| |
| | |
|